TNF blockade in the treatment of rheumatoid arthritis: Infliximab versus etanercept

T. R. Mikuls, L. W. Moreland

Research output: Contribution to journalReview article

53 Citations (Scopus)

Abstract

There is accumulating evidence that tumour necrosis factor (TNF) plays a major role in the pathogenesis of rheumatoid arthritis (RA). Recent biotechnological advances have allowed for the development of agents that directly target TNF, a pro-inflammatory cytokine. In the last 2 years, the US FDA and the EU's Commission of the European Communities have approved two biological agents for the treatment of refractory RA, etanercept and infliximab. Etanercept is a fusion protein, composed of the Fc portion of IgG1 and the extracellular domain of the TNF receptor (p75). Infliximab is a chimeric monoclonal antibody (mAb) composed of murine variable and human constant regions. In placebo-controlled trials, both agents have proven to be effective and well-tolerated in RA patients. This review evaluates the available TNF inhibitors, summarises pertinent clinical trials and underscores differences between the two agents in terms of molecular structure, efficacy, safety data, antigenicity and pharmacokinetics.

Original languageEnglish (US)
Pages (from-to)75-84
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume2
Issue number1
DOIs
StatePublished - May 22 2001

Fingerprint

Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Tumor Necrosis Factor Receptors
Biological Factors
European Union
Molecular Structure
Therapeutics
Pharmacokinetics
Immunoglobulin G
Monoclonal Antibodies
Placebos
Clinical Trials
Cytokines
Safety
Infliximab
Etanercept
Proteins

Keywords

  • Etanercept
  • Infliximab
  • Rheumatoid arthritis
  • Tumour necrosis factor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

TNF blockade in the treatment of rheumatoid arthritis : Infliximab versus etanercept. / Mikuls, T. R.; Moreland, L. W.

In: Expert Opinion on Pharmacotherapy, Vol. 2, No. 1, 22.05.2001, p. 75-84.

Research output: Contribution to journalReview article

@article{2cff817644c14ec7998b187ea106b20f,
title = "TNF blockade in the treatment of rheumatoid arthritis: Infliximab versus etanercept",
abstract = "There is accumulating evidence that tumour necrosis factor (TNF) plays a major role in the pathogenesis of rheumatoid arthritis (RA). Recent biotechnological advances have allowed for the development of agents that directly target TNF, a pro-inflammatory cytokine. In the last 2 years, the US FDA and the EU's Commission of the European Communities have approved two biological agents for the treatment of refractory RA, etanercept and infliximab. Etanercept is a fusion protein, composed of the Fc portion of IgG1 and the extracellular domain of the TNF receptor (p75). Infliximab is a chimeric monoclonal antibody (mAb) composed of murine variable and human constant regions. In placebo-controlled trials, both agents have proven to be effective and well-tolerated in RA patients. This review evaluates the available TNF inhibitors, summarises pertinent clinical trials and underscores differences between the two agents in terms of molecular structure, efficacy, safety data, antigenicity and pharmacokinetics.",
keywords = "Etanercept, Infliximab, Rheumatoid arthritis, Tumour necrosis factor",
author = "Mikuls, {T. R.} and Moreland, {L. W.}",
year = "2001",
month = "5",
day = "22",
doi = "10.1517/14656566.2.1.75",
language = "English (US)",
volume = "2",
pages = "75--84",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - TNF blockade in the treatment of rheumatoid arthritis

T2 - Infliximab versus etanercept

AU - Mikuls, T. R.

AU - Moreland, L. W.

PY - 2001/5/22

Y1 - 2001/5/22

N2 - There is accumulating evidence that tumour necrosis factor (TNF) plays a major role in the pathogenesis of rheumatoid arthritis (RA). Recent biotechnological advances have allowed for the development of agents that directly target TNF, a pro-inflammatory cytokine. In the last 2 years, the US FDA and the EU's Commission of the European Communities have approved two biological agents for the treatment of refractory RA, etanercept and infliximab. Etanercept is a fusion protein, composed of the Fc portion of IgG1 and the extracellular domain of the TNF receptor (p75). Infliximab is a chimeric monoclonal antibody (mAb) composed of murine variable and human constant regions. In placebo-controlled trials, both agents have proven to be effective and well-tolerated in RA patients. This review evaluates the available TNF inhibitors, summarises pertinent clinical trials and underscores differences between the two agents in terms of molecular structure, efficacy, safety data, antigenicity and pharmacokinetics.

AB - There is accumulating evidence that tumour necrosis factor (TNF) plays a major role in the pathogenesis of rheumatoid arthritis (RA). Recent biotechnological advances have allowed for the development of agents that directly target TNF, a pro-inflammatory cytokine. In the last 2 years, the US FDA and the EU's Commission of the European Communities have approved two biological agents for the treatment of refractory RA, etanercept and infliximab. Etanercept is a fusion protein, composed of the Fc portion of IgG1 and the extracellular domain of the TNF receptor (p75). Infliximab is a chimeric monoclonal antibody (mAb) composed of murine variable and human constant regions. In placebo-controlled trials, both agents have proven to be effective and well-tolerated in RA patients. This review evaluates the available TNF inhibitors, summarises pertinent clinical trials and underscores differences between the two agents in terms of molecular structure, efficacy, safety data, antigenicity and pharmacokinetics.

KW - Etanercept

KW - Infliximab

KW - Rheumatoid arthritis

KW - Tumour necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0035003994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035003994&partnerID=8YFLogxK

U2 - 10.1517/14656566.2.1.75

DO - 10.1517/14656566.2.1.75

M3 - Review article

C2 - 11336570

AN - SCOPUS:0035003994

VL - 2

SP - 75

EP - 84

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -